InsiderDB
Sign inStart free trial

Incyte (INCY)

Healthcare · Biotechnology

4 members of Congress have disclosed 8 trades in Incyte (INCY) since 2017: 2 buys and 6 sales. The most recent was disclosed on Nov 5, 2026.

Trades disclosed
8
Members trading
4
Buys / sells
2 / 6
Reported value
$8K–$120K

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow INCY

What else is happening at INCY

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. INCYFinancial report·SEC EDGAR

    INCY: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 29, 2026, 4:03 PM EDTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. INCYCompany announcement·SEC EDGAR

    INCY: Financial results

    Filed 8-K for an event or period dated 2026-10-29. Financial results.

    Public: Oct 29, 2026, 7:03 AM EDTEvent / period: Oct 29, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. INCYRegulatory notice·Federal Register

    Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ATEBRIOZ (Zilurgisertib)

    The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ATEBRIOZ (zilurgisertib), approved September 25, 2026, manufactured by Incyte Corporation meets the criteria for a priority review voucher.

    Public: Oct 28, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  4. INCYLobbying report·Lobbying disclosures

    INCY: third_quarter 2026 lobbying report

    Issues related to 340B Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to CMMI demos (Guarding U.S. Medicare Against Rising Drug Costs (GUARD) and Global Benchmark for Efficient Drug Pricing (GLOBE)); Issues related to Senate Finance Dear Colleague process; Education around access to innovative therapies in dermatology; Issues related to the Orphan Cures Act

    Public: Oct 20, 2026, 3:54 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  5. INCYLobbying report·Lobbying disclosures

    INCY: third_quarter 2026 lobbying report

    Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing including potential legislation to impose Most Favored Nation pricing in Medicare. CMS Guard demonstration project".

    Public: Oct 20, 2026, 3:28 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

Who traded INCY

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.